- Home
- TVGN vs BEAT Comparison
TVGN vs BEAT Comparison
Compare TVGN & BEAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TVGN | BEAT |
|---|---|---|
| Founded | 2020 | 2015 |
| Country | United States | United States |
| Employees | N/A | 16 |
| Industry | Blank Checks | Retail: Computer Software & Peripheral Equipment |
| Sector | Finance | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.9M | 53.2M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | TVGN | BEAT |
|---|---|---|
| Price | $7.82 | $0.88 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $5.63 |
| AVG Volume (30 Days) | 33.0K | ★ 610.9K |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $315.97 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.14 | $0.54 |
| 52 Week High | $12.00 | $4.00 |
Technical Indicators
Market Signals| Indicator | TVGN | BEAT |
|---|---|---|
| Relative Strength Index (RSI) | 49.20 | 41.90 |
| Support Level | $6.41 | $0.81 |
| Resistance Level | $10.08 | $1.28 |
| Average True Range (ATR) | 1.76 | 0.07 |
| MACD | -0.22 | 0.00 |
| Stochastic Oscillator | 27.44 | 5.62 |
Price Performance
Historical ComparisonAbout TVGN Tevogen Bio Holdings Inc.
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About BEAT Heartbeam Inc.
HeartBeam Inc is a medical technology company focused on developing higher resolution ambulatory electrocardiogram (ECG) solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The company's proprietary and patented technology platform captures the heart's electrical activity from three dimensions and synthesizes a 12-lead ECG from these signals. The company has received U.S. Food and Drug Administration (FDA) clearance for its ECG solutions.